WallStreetZenWallStreetZen

NASDAQ: MRSN
Mersana Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Mersana Therapeutics revenue was $34.01M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $2.8M, down 83.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRSN annual revenue was $40.5M, with 9.9% growth year-over-year.

MRSN past revenue growth

How has MRSN's revenue growth performed historically?

Company
-11.21%
Industry
1,361.15%
Market
34.96%
MRSN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MRSN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MRSN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MRSN revenue history

Current Revenue
$34.0M
Current Earnings
-$74.0M
Current Profit Margin
-217.6%

Be the first to know when MRSN announces revenue.

MRSN Revenue History By Year

MRSN Yearly RevenueMRSN RevenueMRSN ChangeMRSN Revenue Growth
2024-12-31$40.50M$3.64M+9.88%
2023-12-31$36.86M$10.27M+38.65%
2022-12-31$26.58M$26.54M+61,716.28%
2021-12-31$43.00k-$785.00k-94.81%
2020-12-31$828.00k-$41.30M-98.03%
2019-12-31$42.12M$31.53M+297.61%
2018-12-31$10.59M-$6.95M-39.62%
2017-12-31$17.55M-$7.63M-30.30%
2016-12-31$25.17M$14.81M+142.99%
2015-12-31$10.36MN/AN/A

1 of 1

Mersana Therapeutics Revenue FAQ

What was MRSN's revenue last quarter?

On Invalid Date, Mersana Therapeutics (NASDAQ: MRSN) reported Q1 2025 revenue of $2.75 million up 70.21% year over year. In the same quarter last year, Mersana Therapeutics's revenue was $9.25 million.

What was Mersana Therapeutics's revenue in 2024?

Mersana Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $40.50 million, a 9.88% increase year over year.

How much does Mersana Therapeutics make in a day?

Based on Mersana Therapeutics annual revenue for the past five years, MRSN makes an average of $57,426.85 per day.

What was Mersana Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Mersana Therapeutics's revenue has grown -11.21% year over year. This is 1,372.35 percentage points lower than the US Biotechnology industry revenue growth rate of 1,361.15%. Mersana Therapeutics's revenue in the past year totaled $34.01 million.

How much does Mersana Therapeutics make in a year?

Mersana Therapeutics's revenue by year for the past five years is:
  • Mersana Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $40.50 million, a 9.88% increase year over year.
  • Mersana Therapeutics's annual revenue for Dec 31, 2023 was $36.86 million, a 38.65% increase from 2022.
  • Mersana Therapeutics's annual revenue for 2022 was $26.58 million, a 61,716.28% increase from 2021.
  • Mersana Therapeutics's annual revenue for 2021 was $43.00 thousand, a 94.81% decrease from 2020.
  • Mersana Therapeutics's annual revenue for 2020 was $828.00 thousand, a 98.03% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.